Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Gaan ze nu echt wachten tot nabeurs om het nieuws te maken?
Sirlander schreef op 6 oktober 2020 16:35 :
[...]
Ik dacht dat ergens in de prospectus stond dat ze die 25 milj. wel hebben opgenomen.
Is hier op het forum gepasseerd...
Klopt helemaal, was ik even vergeten.
Daar zijn ze met hun PB, launch is pas verwacht tegen eind 2020.
Met wat plak en copy werk, toch gelukt om order form van Barhemsys te kunnen delen. Directe mail van Gary Gemignani = garygemignani@acaciapharma.com dus van CEO, Mike Bolinder, zal het waarschijnlijk mikebolinder@acaciapharma.com
Astrix schreef op 6 oktober 2020 16:50 :
Daar zijn ze met hun PB
toeval of niet. Had 1h geleden bericht gestuurd naar Gary om hun te feliciteren en om toch wat hun communicatieaandacht wat de verhogen
"Our first product BAR for ..., was launched in August and we are already registering product sales" Op zijn minst toch ene zot die het gekocht heeft dan ondertussen :)
•BYFAVO expected to be commercially available in the US before the end of the year This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 6 October 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, today announced that the US Drug Enforcement Administration (DEA) has designated its procedural sedative BYFAVO™ (remimazolam injection) as a Schedule IV medicine. This designation is the schedule for drugs with a low potential for abuse and low risk of dependence and is consistent with that granted to many other benzodiazepine drugs, including midazolam and diazepam (Valium®). BYFAVO received approval from the US Food and Drug Administration (FDA) on 2 July 2020 for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. Scheduling by DEA represents the final requirement for BYFAVO to be marketed in the US, with launch expected by the end of 2020. “We are grateful to DEA for its timely determination of the scheduling of BYFAVO and are excited to bring this novel product to the US market,” commented Mike Bolinder, Acacia Pharma’s CEO. “We will start the process of labeling and packaging our stock of commercial product immediately so that we can make BYFAVO available to patients as soon as possible. We anticipate the product being available for sale in the US prior to the end of the year. Our first product, BARHEMSYS® (amisulpride injection) for postoperative nausea & vomiting, was launched in August and we are already registering product sales. We are delighted to be able to provide these two medicines to physicians and their patients in the United States.”
·BYFAVO expected to be commercially available in the US before the end of the year This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 6 October 2020: Acacia Pharma Group plc (“Acacia Pharma” or the “Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, today announced that the US Drug Enforcement Administration (DEA) has designated its procedural sedative BYFAVO™ (remimazolam injection) as a Schedule IV medicine. This designation is the schedule for drugs with a low potential for abuse and low risk of dependence and is consistent with that granted to many other benzodiazepine drugs, including midazolam and diazepam (Valium®). BYFAVO received approval from the US Food and Drug Administration (FDA) on 2 July 2020 for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. Scheduling by DEA represents the final requirement for BYFAVO to be marketed in the US, with launch expected by the end of 2020. “We are grateful to DEA for its timely determination of the scheduling of BYFAVO and are excited to bring this novel product to the US market,” commented Mike Bolinder, Acacia Pharma’s CEO. “We will start the process of labeling and packaging our stock of commercial product immediately so that we can make BYFAVO available to patients as soon as possible. We anticipate the product being available for sale in the US prior to the end of the year. Our first product, BARHEMSYS® (amisulpride injection) for postoperative nausea & vomiting, was launched in August and we are already registering product sales. We are delighted to be able to provide these two medicines to physicians and their patients in the United States.”
En meteen beweging in de koers !!
Ik bezit bio aandelen van bedrijven die hoger genoteerd staan en geen 1 medicijn verkopen op de markt ;)
was launched in August and we are already registering product sales. We are delighted to be able to provide these two medicines to physicians and their patients in the United States... Hij kon toch een beetje positiever zijn, genre already registering great product sales
Ik zeg gewoon hehe. Maar nog steeds belachelijk laag. Maar een goed begin.
Ze zijn wakker in de VS. ;-)
En voor harry die op 1.90 wil kopen. Begin je volgende ritjes maar wat hoger, lager dan 2.12 gaat je niet meer lukken.
Het moest toch een keer gebeuren, die stijging. Maar kwam voor mij vanmiddag toch nog wel onverwacht.
De solden zijn gedaan !!!!!!
Dit klinkt als muziek in de oren :D
Madebeliefje schreef op 6 oktober 2020 17:02 :
En voor harry die op 1.90 wil kopen.
Begin je volgende ritjes maar wat hoger, lager dan 2.12 gaat je niet meer lukken.
Voor Harry niet alleen..had ze op kopen staan a 2 euro deze week maar helaas niet gehaald nondeju
To infinity... and beyond!
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Indices
AEX
869,54
-0,51%
EUR/USD
1,0688
-0,09%
FTSE 100
8.066,02
+0,32%
Germany40^
17.884,60
-1,13%
Gold spot
2.324,76
+0,37%
NY-Nasdaq Composite
15.712,75
+0,10%
Stijgers
Dalers